Ignite Creation Date:
2025-12-25 @ 2:18 AM
Ignite Modification Date:
2026-07-02 @ 4:50 AM
Study NCT ID:
NCT01985334
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2013-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D029424', 'term': 'Pulmonary Disease, Chronic Obstructive'}], 'ancestors': [{'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D006024', 'term': 'Glycopyrrolate'}, {'id': 'C046122', 'term': '3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole'}], 'ancestors': [{'id': 'D000644', 'term': 'Quaternary Ammonium Compounds'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D009861', 'term': 'Onium Compounds'}, {'id': 'D011759', 'term': 'Pyrrolidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '862-778-8300', 'title': 'Study Director', 'organization': 'Novartis Pharmaceuticals'}, 'certainAgreement': {'otherDetails': "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA', 'otherNumAtRisk': 125, 'otherNumAffected': 19, 'seriousNumAtRisk': 125, 'seriousNumAffected': 4}, {'id': 'EG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)', 'otherNumAtRisk': 385, 'otherNumAffected': 67, 'seriousNumAtRisk': 385, 'seriousNumAffected': 9}, {'id': 'EG002', 'title': 'B1 (Any LAMA or@ LABA and mMRC eq 1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA', 'otherNumAtRisk': 417, 'otherNumAffected': 63, 'seriousNumAtRisk': 417, 'seriousNumAffected': 11}, {'id': 'EG003', 'title': 'B2 (Glycopyrronium@ and mMRC eq 1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)', 'otherNumAtRisk': 1248, 'otherNumAffected': 163, 'seriousNumAtRisk': 1248, 'seriousNumAffected': 30}, {'id': 'EG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC', 'otherNumAtRisk': 269, 'otherNumAffected': 29, 'seriousNumAtRisk': 269, 'seriousNumAffected': 6}, {'id': 'EG005', 'title': 'C2 (Indacaterol/@Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)', 'otherNumAtRisk': 816, 'otherNumAffected': 119, 'seriousNumAtRisk': 816, 'seriousNumAffected': 22}, {'id': 'EG006', 'title': 'D1 (Any LAMA or@ LABA and mMRC gt 1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA', 'otherNumAtRisk': 269, 'otherNumAffected': 20, 'seriousNumAtRisk': 269, 'seriousNumAffected': 10}, {'id': 'EG007', 'title': 'D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).', 'otherNumAtRisk': 814, 'otherNumAffected': 120, 'seriousNumAtRisk': 814, 'seriousNumAffected': 34}], 'otherEvents': [{'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 38}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 24}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 71}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 11}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 37}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 10}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 54}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 5}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 10}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Tracheitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 11}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 8}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 33}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 44}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 27}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 7}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 7}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 10}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 4}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Productive cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 7}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Immune thrombocytopenic purpura', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Acute coronary syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Angina pectoris', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Angina unstable', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Aortic valve incompetence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Aortic valve stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Arrhythmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Arteriosclerosis coronary artery', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Coronary artery disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Ischaemic cardiomyopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Left ventricular failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Myocardial ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Supraventricular tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Congenital central nervous system anomaly', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hydrocele', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Abdominal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Abdominal incarcerated hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Diverticulum oesophageal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Faecaloma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Inguinal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Sudden death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Bile duct stone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Biliary tract disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hepatic cirrhosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Anaphylactic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Drug hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Diverticulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Mediastinal abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Oesophageal candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Bursa injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Facial bones fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Femur fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hip fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Jaw fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Ligament rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Rib fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Splenic rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Traumatic intracranial haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Wound dehiscence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Blood pressure increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Heart rate decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pseudarthrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Synovitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Bladder neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Brain neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Breast cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 2}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Bronchial carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Colon cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Laryngeal cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Lung adenocarcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Metastases to bone', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Oropharyngeal cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Prostate cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Squamous cell carcinoma of the tongue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cerebral ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cerebrovascular disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Cerebrovascular insufficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Embolic cerebral infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Loss of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Ruptured cerebral aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Vascular dementia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Vascular encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Alcoholism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pneumothorax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pulmonary haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Pulmonary oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Respiratory depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Blister', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Aortic aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Aortic stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Circulatory collapse', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Femoral artery aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Hypertensive crisis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Intermittent claudication', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Peripheral arterial occlusive disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Peripheral artery aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Peripheral artery stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Peripheral artery thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}, {'term': 'Thrombophlebitis superficial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 385, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 417, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 1248, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 816, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 269, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 814, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (17.1)'}], 'frequencyThreshold': '1'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '369', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'OG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}], 'classes': [{'categories': [{'measurements': [{'value': '1.8264', 'groupId': 'OG000', 'lowerLimit': '1.7797', 'upperLimit': '1.8732'}, {'value': '1.8916', 'groupId': 'OG001', 'lowerLimit': '1.8647', 'upperLimit': '1.9185'}]}]}], 'analyses': [{'pValue': '0.0180', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval', 'unitOfMeasure': 'Liters', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '420', 'groupId': 'OG000'}, {'value': '1254', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'OG001', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}], 'classes': [{'categories': [{'measurements': [{'value': '1.8004', 'groupId': 'OG000', 'lowerLimit': '1.7768', 'upperLimit': '1.8239'}, {'value': '1.8215', 'groupId': 'OG001', 'lowerLimit': '1.8078', 'upperLimit': '1.8352'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE', 'nonInferiorityComment': 'H0: Glycopyrronium (50 μg o.d.) \\[randomized group B2\\] was inferior to LABA or LAMA (random group B1) with respect to mean trough FEV1 after 12 weeks of treatment.\n\nH0: μFEV1, NVA237 - μFEV1, LABA and/or LAMA \\< -40 mL Ha: Glycopyrronium (50 μg o.d.) \\[randomized group B2\\] is non-inferior to LABA or LAMA (random group B1) with respect to mean trough FEV1 after 12 weeks of treatment.\n\nHa: μFEV1, NVA237 - μFEV1, LABA and/or LAMA ≥ -40 mL'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval', 'unitOfMeasure': 'Liters', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '269', 'groupId': 'OG000'}, {'value': '811', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'OG001', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}], 'classes': [{'categories': [{'measurements': [{'value': '1.6847', 'groupId': 'OG000', 'lowerLimit': '1.6542', 'upperLimit': '1.7153'}, {'value': '1.7558', 'groupId': 'OG001', 'lowerLimit': '1.7378', 'upperLimit': '1.7737'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.', 'unitOfMeasure': 'Liters', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '268', 'groupId': 'OG000'}, {'value': '811', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'OG001', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'classes': [{'categories': [{'measurements': [{'value': '1.6728', 'groupId': 'OG000', 'lowerLimit': '1.6461', 'upperLimit': '1.6994'}, {'value': '1.7742', 'groupId': 'OG001', 'lowerLimit': '1.7587', 'upperLimit': '1.7896'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.', 'unitOfMeasure': 'Liters', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '369', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'OG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}], 'classes': [{'categories': [{'measurements': [{'value': '0.5117', 'groupId': 'OG000', 'lowerLimit': '-0.0073', 'upperLimit': '1.0306'}, {'value': '2.3005', 'groupId': 'OG001', 'lowerLimit': '2.0015', 'upperLimit': '2.5995'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '420', 'groupId': 'OG000'}, {'value': '1254', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'OG001', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}], 'classes': [{'categories': [{'measurements': [{'value': '0.6969', 'groupId': 'OG000', 'lowerLimit': '0.4169', 'upperLimit': '0.9769'}, {'value': '1.4351', 'groupId': 'OG001', 'lowerLimit': '1.2718', 'upperLimit': '1.5984'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE', 'nonInferiorityComment': 'A difference of 0.6 points in TDI was adopted as boundary for non-inferiority'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '269', 'groupId': 'OG000'}, {'value': '811', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'OG001', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}], 'classes': [{'categories': [{'measurements': [{'value': '0.8508', 'groupId': 'OG000', 'lowerLimit': '0.4676', 'upperLimit': '1.2340'}, {'value': '1.9491', 'groupId': 'OG001', 'lowerLimit': '1.7207', 'upperLimit': '2.1775'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'PRIMARY', 'title': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '268', 'groupId': 'OG000'}, {'value': '811', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'OG001', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.8632', 'groupId': 'OG000', 'lowerLimit': '0.5098', 'upperLimit': '1.2166'}, {'value': '2.1209', 'groupId': 'OG001', 'lowerLimit': '1.9130', 'upperLimit': '2.3288'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'statisticalMethod': 'linear mixed model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1623', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'A2 + B2', 'description': 'A2 (glycopyrronium)+B2 (glycopyrronium and mMRC=1'}, {'id': 'OG001', 'title': 'A1 + B1', 'description': 'A1(any SABA and/or SAMA+B1 (any LAMA or LABA and mMRC=1'}], 'classes': [{'categories': [{'measurements': [{'value': '1.8373', 'groupId': 'OG000', 'lowerLimit': '1.8250', 'upperLimit': '1.8496'}, {'value': '1.8065', 'groupId': 'OG001', 'lowerLimit': '1.7853', 'upperLimit': '1.8276'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval', 'unitOfMeasure': 'Liters', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1623', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'A2 +B2', 'description': 'A2 (glycopyrronium)+B2 (glycopyrronium and mMRC=1'}, {'id': 'OG001', 'title': 'A1 +B1', 'description': 'A1(any SABA and/or SAMA+B1 (any LAMA or LABA and mMRC=1)'}], 'classes': [{'categories': [{'measurements': [{'value': '1.6315', 'groupId': 'OG000', 'lowerLimit': '1.4874', 'upperLimit': '1.7756'}, {'value': '0.6562', 'groupId': 'OG001', 'lowerLimit': '0.4085', 'upperLimit': '0.9039'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1622', 'groupId': 'OG000'}, {'value': '537', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'C2 +D2', 'description': 'C2 (indacaterol/glycopyrronium)+D2 (indacaterol/glycopyrronium and mMRC\\>1)'}, {'id': 'OG001', 'title': 'C1 + D1', 'description': 'C1 (any LABA and ICS)+D1 (any LAMA or LABA and mMRC\\>1)'}], 'classes': [{'categories': [{'measurements': [{'value': '1.7650', 'groupId': 'OG000', 'lowerLimit': '1.7532', 'upperLimit': '1.7768'}, {'value': '1.6789', 'groupId': 'OG001', 'lowerLimit': '1.6587', 'upperLimit': '1.6992'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '12 Weeks', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.', 'unitOfMeasure': 'Liters', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1622', 'groupId': 'OG000'}, {'value': '537', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'C2 +D2', 'description': 'C2 (indacaterol/glycopyrronium) + D2 (indacaterol/glycopyrronium and mMRC\\>1)'}, {'id': 'OG001', 'title': 'C1 + D1', 'description': 'C1 (any LABA and ICS) + D1 (any LAMA or LABA and mMRC\\>1)'}], 'classes': [{'categories': [{'measurements': [{'value': '2.0354', 'groupId': 'OG000', 'lowerLimit': '1.8811', 'upperLimit': '2.1896'}, {'value': '0.8588', 'groupId': 'OG001', 'lowerLimit': '0.5983', 'upperLimit': '1.1192'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '369', 'groupId': 'OG001'}, {'value': '420', 'groupId': 'OG002'}, {'value': '1254', 'groupId': 'OG003'}, {'value': '269', 'groupId': 'OG004'}, {'value': '811', 'groupId': 'OG005'}, {'value': '268', 'groupId': 'OG006'}, {'value': '811', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'OG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG002', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'OG003', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'OG005', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}, {'id': 'OG006', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'OG007', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1', 'spread': '4.6', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '5.3', 'groupId': 'OG001'}, {'value': '0.1', 'spread': '4.9', 'groupId': 'OG002'}, {'value': '-0.5', 'spread': '4.6', 'groupId': 'OG003'}, {'value': '-0.4', 'spread': '4.8', 'groupId': 'OG004'}, {'value': '-1.4', 'spread': '5.4', 'groupId': 'OG005'}, {'value': '-0.9', 'spread': '5.0', 'groupId': 'OG006'}, {'value': '-1.9', 'spread': '5.3', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (baseline) and Week 12', 'description': 'Total score of COPD Assessment Test (CAT) will be measured at baseline and at week 12. This questionnaire is completed by the patient. The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.', 'unitOfMeasure': 'Score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '369', 'groupId': 'OG001'}, {'value': '420', 'groupId': 'OG002'}, {'value': '1254', 'groupId': 'OG003'}, {'value': '269', 'groupId': 'OG004'}, {'value': '811', 'groupId': 'OG005'}, {'value': '268', 'groupId': 'OG006'}, {'value': '811', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'OG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG002', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'OG003', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'OG005', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}, {'id': 'OG006', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'OG007', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.0', 'spread': '0.6', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.7', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '0.7', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '0.7', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '0.7', 'groupId': 'OG004'}, {'value': '-0.2', 'spread': '0.8', 'groupId': 'OG005'}, {'value': '-0.1', 'spread': '0.8', 'groupId': 'OG006'}, {'value': '-0.3', 'spread': '0.8', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (baseline) and Week 12', 'description': 'The Clinical COPD Questionnaire (CCQ) is a self-administered 10-item questionnaire developed to measure clinical control in patients with COPD. Patients will be instructed to recall their experiences during the previous week. They respond to each question using a 7-point scale from 0 = asymptomatic/no imitation to 6 = extremely symptomatic/totally limited. The questionnaire is divided into 3 domains (symptoms \\[items 1, 2, 5, and 6\\] functional \\[items 7, 8, 9, and 10\\] and mental state \\[items 3 and 4\\]). The overall clinical COPD control score and the scores of the domains are calculated by adding all the scores together and dividing this sum by the number of questions.\n\nThus, the overall clinical COPD control score as well as the score on each of the three domains varies between 0 (very good control) to 6 (extremely poor control).', 'unitOfMeasure': 'Score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '369', 'groupId': 'OG001'}, {'value': '420', 'groupId': 'OG002'}, {'value': '1254', 'groupId': 'OG003'}, {'value': '269', 'groupId': 'OG004'}, {'value': '811', 'groupId': 'OG005'}, {'value': '268', 'groupId': 'OG006'}, {'value': '811', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'OG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG002', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'OG003', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'OG005', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}, {'id': 'OG006', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'OG007', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'classes': [{'categories': [{'measurements': [{'value': '1.8', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '1.3', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '1.2', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '1.1', 'groupId': 'OG003'}, {'value': '1.6', 'spread': '1.7', 'groupId': 'OG004'}, {'value': '1.1', 'spread': '1.4', 'groupId': 'OG005'}, {'value': '1.4', 'spread': '1.4', 'groupId': 'OG006'}, {'value': '1.1', 'spread': '1.3', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': '12 weeks', 'description': 'Mean number of puffs of rescue medication use will be measured using eDiary data over 12 weeks of treatment.', 'unitOfMeasure': 'Number of puffs', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '369', 'groupId': 'OG001'}, {'value': '420', 'groupId': 'OG002'}, {'value': '1254', 'groupId': 'OG003'}, {'value': '269', 'groupId': 'OG004'}, {'value': '811', 'groupId': 'OG005'}, {'value': '268', 'groupId': 'OG006'}, {'value': '811', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'OG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG002', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'OG003', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'OG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'OG005', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}, {'id': 'OG006', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'OG007', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-0.10', 'spread': '0.22', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.19', 'groupId': 'OG002'}, {'value': '-0.05', 'spread': '0.20', 'groupId': 'OG003'}, {'value': '-0.05', 'spread': '0.19', 'groupId': 'OG004'}, {'value': '-0.07', 'spread': '0.22', 'groupId': 'OG005'}, {'value': '-0.04', 'spread': '0.19', 'groupId': 'OG006'}, {'value': '-0.09', 'spread': '0.21', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 12 weeks', 'description': 'Patient-reported symptoms of COPD combined will be measured using eDiary data reported over the 12 week treatment period. The mean total symptom scores and mean individual symptom scores for the patient were calculated for the whole study period. The mean change from baseline in the total scores and in the individual scores were summarized by treatment and were analyzed for the percentage of nights with no nighttime awakenings and percentage of days with no symptoms.', 'unitOfMeasure': 'Percentage of days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and who were getting the appropriate medication, be it glycopyrronium, indacaterol + glycopyrronium or comparative treatment (baseline therapy) in the respective comparisons of the different groups'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'FG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'FG002', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'FG003', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'FG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'FG005', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}, {'id': 'FG006', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'FG007', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '130'}, {'groupId': 'FG001', 'numSubjects': '387'}, {'groupId': 'FG002', 'numSubjects': '420'}, {'groupId': 'FG003', 'numSubjects': '1262'}, {'groupId': 'FG004', 'numSubjects': '274'}, {'groupId': 'FG005', 'numSubjects': '822'}, {'groupId': 'FG006', 'numSubjects': '274'}, {'groupId': 'FG007', 'numSubjects': '820'}]}, {'type': 'The Intention-to-treat (ITT) Population', 'achievements': [{'groupId': 'FG000', 'numSubjects': '122'}, {'groupId': 'FG001', 'numSubjects': '369'}, {'groupId': 'FG002', 'numSubjects': '420'}, {'groupId': 'FG003', 'numSubjects': '1254'}, {'groupId': 'FG004', 'numSubjects': '269'}, {'groupId': 'FG005', 'numSubjects': '811'}, {'groupId': 'FG006', 'numSubjects': '268'}, {'groupId': 'FG007', 'numSubjects': '811'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '107'}, {'groupId': 'FG001', 'numSubjects': '303'}, {'groupId': 'FG002', 'numSubjects': '367'}, {'groupId': 'FG003', 'numSubjects': '1033'}, {'groupId': 'FG004', 'numSubjects': '234'}, {'groupId': 'FG005', 'numSubjects': '666'}, {'groupId': 'FG006', 'numSubjects': '237'}, {'groupId': 'FG007', 'numSubjects': '699'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}, {'groupId': 'FG001', 'numSubjects': '84'}, {'groupId': 'FG002', 'numSubjects': '53'}, {'groupId': 'FG003', 'numSubjects': '229'}, {'groupId': 'FG004', 'numSubjects': '40'}, {'groupId': 'FG005', 'numSubjects': '156'}, {'groupId': 'FG006', 'numSubjects': '37'}, {'groupId': 'FG007', 'numSubjects': '121'}]}], 'dropWithdraws': [{'type': 'Administrative problems', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '3'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '2'}]}, {'type': 'Worsening of disease', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '17'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '4'}, {'groupId': 'FG007', 'numSubjects': '7'}]}, {'type': 'Protocol deviation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '31'}, {'groupId': 'FG002', 'numSubjects': '25'}, {'groupId': 'FG003', 'numSubjects': '84'}, {'groupId': 'FG004', 'numSubjects': '17'}, {'groupId': 'FG005', 'numSubjects': '47'}, {'groupId': 'FG006', 'numSubjects': '15'}, {'groupId': 'FG007', 'numSubjects': '42'}]}, {'type': 'Moderate / severe COPD exacerbation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '12'}, {'groupId': 'FG003', 'numSubjects': '40'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '40'}, {'groupId': 'FG006', 'numSubjects': '8'}, {'groupId': 'FG007', 'numSubjects': '19'}]}, {'type': 'Subject withdrawal of consent', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '28'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '19'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '20'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '26'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '18'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '15'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '10'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '2'}]}, {'type': 'Medication non-compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '3'}]}, {'type': 'Use of prohibited treatment', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Investigator decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '7'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '4'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '3'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'BG000'}, {'value': '387', 'groupId': 'BG001'}, {'value': '420', 'groupId': 'BG002'}, {'value': '1262', 'groupId': 'BG003'}, {'value': '274', 'groupId': 'BG004'}, {'value': '822', 'groupId': 'BG005'}, {'value': '274', 'groupId': 'BG006'}, {'value': '820', 'groupId': 'BG007'}, {'value': '4389', 'groupId': 'BG008'}]}], 'groups': [{'id': 'BG000', 'title': 'A1 (Any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination at enrollment and randomized to remain in their baseline therapy with any SABA and/or SAMA'}, {'id': 'BG001', 'title': 'A2 (Glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'BG002', 'title': 'B1 (Any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA'}, {'id': 'BG003', 'title': 'B2 (Glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)'}, {'id': 'BG004', 'title': 'C1 (Any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC'}, {'id': 'BG005', 'title': 'C2 (Indacaterol/Glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)'}, {'id': 'BG006', 'title': 'D1 (Any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA'}, {'id': 'BG007', 'title': 'D2 (Indacaterol/Glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).'}, {'id': 'BG008', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '64.2', 'spread': '8.2', 'groupId': 'BG000'}, {'value': '63.2', 'spread': '8.3', 'groupId': 'BG001'}, {'value': '64.6', 'spread': '8.1', 'groupId': 'BG002'}, {'value': '64.4', 'spread': '8.2', 'groupId': 'BG003'}, {'value': '64.4', 'spread': '9.0', 'groupId': 'BG004'}, {'value': '64.7', 'spread': '8.7', 'groupId': 'BG005'}, {'value': '65.1', 'spread': '7.6', 'groupId': 'BG006'}, {'value': '65.4', 'spread': '8.3', 'groupId': 'BG007'}, {'value': '64.6', 'spread': '8.3', 'groupId': 'BG008'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '48', 'groupId': 'BG000'}, {'value': '119', 'groupId': 'BG001'}, {'value': '131', 'groupId': 'BG002'}, {'value': '376', 'groupId': 'BG003'}, {'value': '106', 'groupId': 'BG004'}, {'value': '286', 'groupId': 'BG005'}, {'value': '95', 'groupId': 'BG006'}, {'value': '276', 'groupId': 'BG007'}, {'value': '1437', 'groupId': 'BG008'}]}, {'title': 'Male', 'measurements': [{'value': '82', 'groupId': 'BG000'}, {'value': '268', 'groupId': 'BG001'}, {'value': '289', 'groupId': 'BG002'}, {'value': '886', 'groupId': 'BG003'}, {'value': '168', 'groupId': 'BG004'}, {'value': '536', 'groupId': 'BG005'}, {'value': '179', 'groupId': 'BG006'}, {'value': '544', 'groupId': 'BG007'}, {'value': '2952', 'groupId': 'BG008'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 4389}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-02-14', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-03', 'completionDateStruct': {'date': '2016-04-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-03-18', 'studyFirstSubmitDate': '2013-11-04', 'resultsFirstSubmitDate': '2017-04-05', 'studyFirstSubmitQcDate': '2013-11-08', 'lastUpdatePostDateStruct': {'date': '2019-03-19', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-03-18', 'studyFirstPostDateStruct': {'date': '2013-11-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-03-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-04-29', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval'}, {'measure': 'Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval'}, {'measure': 'Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.'}, {'measure': 'Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'timeFrame': 'Week 12 (Visit 4)', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.'}, {'measure': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.'}, {'measure': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.'}, {'measure': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.'}, {'measure': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.'}], 'secondaryOutcomes': [{'measure': 'Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'timeFrame': '12 Weeks', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval'}, {'measure': 'Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.'}, {'measure': 'Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.', 'timeFrame': '12 Weeks', 'description': 'Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.'}, {'measure': 'Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC', 'timeFrame': 'Day 1 (baseline) and week 12', 'description': 'Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.'}, {'measure': 'Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'timeFrame': 'Day 1 (baseline) and Week 12', 'description': 'Total score of COPD Assessment Test (CAT) will be measured at baseline and at week 12. This questionnaire is completed by the patient. The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.'}, {'measure': 'Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'timeFrame': 'Day 1 (baseline) and Week 12', 'description': 'The Clinical COPD Questionnaire (CCQ) is a self-administered 10-item questionnaire developed to measure clinical control in patients with COPD. Patients will be instructed to recall their experiences during the previous week. They respond to each question using a 7-point scale from 0 = asymptomatic/no imitation to 6 = extremely symptomatic/totally limited. The questionnaire is divided into 3 domains (symptoms \\[items 1, 2, 5, and 6\\] functional \\[items 7, 8, 9, and 10\\] and mental state \\[items 3 and 4\\]). The overall clinical COPD control score and the scores of the domains are calculated by adding all the scores together and dividing this sum by the number of questions.\n\nThus, the overall clinical COPD control score as well as the score on each of the three domains varies between 0 (very good control) to 6 (extremely poor control).'}, {'measure': 'Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'timeFrame': '12 weeks', 'description': 'Mean number of puffs of rescue medication use will be measured using eDiary data over 12 weeks of treatment.'}, {'measure': 'Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC', 'timeFrame': 'Baseline, 12 weeks', 'description': 'Patient-reported symptoms of COPD combined will be measured using eDiary data reported over the 12 week treatment period. The mean total symptom scores and mean individual symptom scores for the patient were calculated for the whole study period. The mean change from baseline in the total scores and in the individual scores were summarized by treatment and were analyzed for the percentage of nights with no nighttime awakenings and percentage of days with no symptoms.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Moderate COPD, glycopyrronium bromide, indacaterol maleate and glycopyrronium bromide FDC, NVA237, QVA149'], 'conditions': ['COPD']}, 'referencesModule': {'references': [{'pmid': '29713156', 'type': 'DERIVED', 'citation': 'Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.'}, {'pmid': '28720132', 'type': 'DERIVED', 'citation': 'Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.'}]}, 'descriptionModule': {'briefSummary': 'The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their current COPD therapy. This study aims to provide data on how non-exacerbating, but still symptomatic patients with moderate COPD switching from their current COPD treatment to glycopyrronium bromide or indacaterol maleate and glycopyrronium bromide FDC maintain or improve their symptoms. Another purpose of this study is to increase awareness and usage of validated COPD symptoms tools and dyspnea questionnaires in order to facilitate clinical assessment and improve early diagnosis of symptomatic patients.', 'detailedDescription': 'The treatment epoch will last 12 weeks. The total duration of the study for each patient is 12 weeks (from randomization) plus 30 days of safety follow-up.\n\nThe study has three phases: screening phase (=wash-out period, if required), treatment phase and safety follow-up phase.\n\nEligible patients will be randomized to either receive glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed dose combination or to remain in their baseline therapy, in an allocation ratio of 3:1 for each cluster (Groups A, B, C, and D), based on their COPD symptoms and baseline treatment:\n\nGroup A: Patients treated with any SABA ( Short-acting β2-adrenergic agonist) and/or SAMA (Short-acting muscarinic antagonist) as monotherapy or in free or fixed dose combination (FDC) will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group B: Patients treated with any LABA (Long-acting β2-adrenergic agonist) or LAMA (Long-acting muscarinic antagonist) monotherapy and mMRC score =1 point will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group C: Patients treated with any LABA and ICS (Inhaled corticosteroid) in free or FDC will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Group D: Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Due to low recruitment in Groups A and B that would lead to a significant delay of trial completion, a protocol amendment was made in order to close the recruitment of Groups A and B at the time the randomization in Groups C and D would be completed. Recruitment of the Groups C and D continued as originally planned'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '95 Years', 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male and female adults aged ≥ 40 years\n* Patients with moderate COPD according to the GOLD criteria 2013\n* Current or ex-smokers who have a smoking history of at least 10 pack years\n* Patients with airflow limitation indicated by a postbronchodilator FEV1 ≥50% and \\<80% of the predicted normal value and a post-bronchodilator FEV1/FVC \\<0.7 at Visit 2. Post- bronchodilator refers to within 10-15 min of inhalation of 400 μg (4x100 μg) of salbutamol\n* Patients who, at Visit 1, have been for at least 3 months on a stable dose of one of the following COPD baseline treatments: \\*Any SABA monotherapy (such as, but not limited to, salbutamol) \\*Any SAMA monotherapy (such as, but not limited to, ipratropium) \\*Any SABA and SAMA in free or FDC (such as, but not limited to, salbutamol/ipratropium) \\*Any LABA monotherapy (such as, but not limited to, formoterol, salmeterol, indacaterol) \\*Any LAMA monotherapy (such as, but not limited to, tiotropium, aclidinium) except glycopyrronium bromide (NVA237) \\*Any LABA and ICS in free (ICS such as, but not limited to, beclomethasone, fluticasone) or FDC (such as, but not limited to, salmeterol/fluticasone, formoterol/budesonide).\n* Patients with an mMRC score ≥1 at Visit 1.\n\nExclusion Criteria:\n\n* Patients with conditions contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs or to drugs of similar chemical classes or any component thereof: Anti-cholinergic agents, Long- and short-acting 2-adrenergic agonists, Sympathomimetic amines, Lactose or any of the other excipients of the trial medication.\n* Patients with narrow-angle glaucoma or urinary retention, severe renal impairment (history of estimated glomerular filtration rate below 30 ml/min/1.73 m2 within 12 months prior to visit 1), including those with end-stage renal disease requiring dialysis.\n* Patients with active/ clinical history of asthma.If the Investigator finds clear and compelling evidence that a patient was misdiagnosed with asthma in the past, then the burden of proof is on the Investigator to properly document this previous misdiagnosis. This documentation must include the rationale for this change in diagnosis including reference to the differential diagnosis that supports this decision.\n* Patients with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.\n* Patients who have a post-bronchodilator FEV1 decrease more than 10% compared to pre-bronchodilator FEV1 result at Visit 2 (see Appendix 5 for details).\n* A documented history of \\>1 COPD exacerbation requiring treatment with systemic corticosteroids or antibiotics and/or hospitalization in the previous 12 months.\n* Patients who have NOT had a COPD exacerbation in the previous 12 months and develop a COPD exacerbation between screening (Visit 1) and (Visit 2) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation. (Patients suffering an exacerbation between Visit 1 and Visit 2 can only be re-screened in case it is the first one in the previous 12 months. In case this COPD exacerbation has led to an alteration of the patient COPD treatment, before this patient can be re-screened 3 months of stable COPD treatment will be required as described in Inclusion Criterion 6).\n* Patients who, in the judgment of the investigator, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to): \\*Unstable ischemic heart disease, left ventricular failure (NYHA Class III \\& IV), history of myocardial infarction,arrhythmia (excluding chronic stable atrial fibrillation). Patients with such events not considered clinically significant by the investigator may be considered for inclusion in the study.\\*Uncontrolled hypo-or hyperthyroidism, hypokalaemia or hyperadrenergic state. \\*Any condition which might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study\n* History of resting QTc (Fridericia preferred, but Bazett acceptable) \\>450 msec (male) or \\>460 msec (female) within five years before Visit 1.\n* Patients who are treated with glycopyrronium bromide (NVA237) at visit 1 are not allowed to be included into the trialPatients on non-selective beta-blockers. Those patients may enter the study after non-selective beta-blocker withdrawal during a 7-day wash-out period.\n* Patients receiving any other prohibited COPD-related medications specified in Table 5-2 Prohibited COPD related medications must undergo the required wash-out period prior to Visit 2.\n* Patients who are, in the opinion of the investigator known to be unreliable or non-compliant.\n* Patients with a body mass index (BMI) of more than 40 kg/m2.\n* Use of other investigational drugs within 5 half-lives of enrollment or within 30 days, whichever is longer.\n* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.'}, 'identificationModule': {'nctId': 'NCT01985334', 'briefTitle': 'Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': 'A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptoms and Health Status in Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD) Switching From Treatment With Any Standard COPD Regimen', 'orgStudyIdInfo': {'id': 'CQVA149A3401'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A1 (any SABA and/or SAMA)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment', 'interventionNames': ['Drug: Glycopyrronium', 'Drug: SABA', 'Drug: SAMA']}, {'type': 'EXPERIMENTAL', 'label': 'A2 (glycopyrronium)', 'description': 'Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)', 'interventionNames': ['Drug: Glycopyrronium', 'Drug: SABA', 'Drug: LABA', 'Drug: SAMA']}, {'type': 'EXPERIMENTAL', 'label': 'B1 (any LAMA or LABA and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA', 'interventionNames': ['Drug: LABA', 'Drug: Indacaterol maleate and glycopyrronium bromide', 'Drug: LAMA', 'Drug: ICS']}, {'type': 'EXPERIMENTAL', 'label': 'B2 (glycopyrronium and mMRC=1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)', 'interventionNames': ['Drug: LABA', 'Drug: Indacaterol maleate and glycopyrronium bromide', 'Drug: LAMA']}, {'type': 'EXPERIMENTAL', 'label': 'C1 (any LABA and ICS)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC', 'interventionNames': ['Drug: LABA', 'Drug: ICS']}, {'type': 'EXPERIMENTAL', 'label': 'C2 (indacaterol/glycopyrronium)', 'description': 'Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)', 'interventionNames': ['Drug: LABA', 'Drug: ICS']}, {'type': 'EXPERIMENTAL', 'label': 'D1 (any LAMA or LABA and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA', 'interventionNames': ['Drug: LAMA']}, {'type': 'EXPERIMENTAL', 'label': 'D2 (indacaterol/glycopyrronium and mMRC>1)', 'description': 'Patients treated with any LABA or LAMA monotherapy and mMRC score \\>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).', 'interventionNames': ['Drug: LAMA']}], 'interventions': [{'name': 'Glycopyrronium', 'type': 'DRUG', 'otherNames': ['glycopyrronium bromide'], 'description': 'Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day', 'armGroupLabels': ['A1 (any SABA and/or SAMA)', 'A2 (glycopyrronium)']}, {'name': 'SABA', 'type': 'DRUG', 'description': 'Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy', 'armGroupLabels': ['A1 (any SABA and/or SAMA)', 'A2 (glycopyrronium)']}, {'name': 'LABA', 'type': 'DRUG', 'description': 'Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy', 'armGroupLabels': ['A2 (glycopyrronium)', 'B1 (any LAMA or LABA and mMRC=1)', 'B2 (glycopyrronium and mMRC=1)', 'C1 (any LABA and ICS)', 'C2 (indacaterol/glycopyrronium)']}, {'name': 'Indacaterol maleate and glycopyrronium bromide', 'type': 'DRUG', 'description': 'Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day', 'armGroupLabels': ['B1 (any LAMA or LABA and mMRC=1)', 'B2 (glycopyrronium and mMRC=1)']}, {'name': 'LAMA', 'type': 'DRUG', 'description': 'Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy', 'armGroupLabels': ['B1 (any LAMA or LABA and mMRC=1)', 'B2 (glycopyrronium and mMRC=1)', 'D1 (any LAMA or LABA and mMRC>1)', 'D2 (indacaterol/glycopyrronium and mMRC>1)']}, {'name': 'SAMA', 'type': 'DRUG', 'description': 'Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy', 'armGroupLabels': ['A1 (any SABA and/or SAMA)', 'A2 (glycopyrronium)']}, {'name': 'ICS', 'type': 'DRUG', 'description': 'Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy', 'armGroupLabels': ['B1 (any LAMA or LABA and mMRC=1)', 'C1 (any LABA and ICS)', 'C2 (indacaterol/glycopyrronium)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '3300', 'city': 'Amstetten', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.1229, 'lon': 14.87206}}, {'zip': '6800', 'city': 'Feldkirch', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.23306, 'lon': 9.6}}, {'zip': '5400', 'city': 'Hallein', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.68333, 'lon': 13.1}}, {'zip': '4560', 'city': 'Kirchdorf an der Krems', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.90558, 'lon': 14.12228}}, {'zip': '8700', 'city': 'Leoben', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.3765, 'lon': 15.09144}}, {'zip': '4020', 'city': 'Linz', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}, {'zip': '4320', 'city': 'Perg', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.25, 'lon': 14.63333}}, {'zip': '5020', 'city': 'Salzburg', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.79941, 'lon': 13.04399}}, {'zip': '4600', 'city': 'Wels', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.16667, 'lon': 14.03333}}, {'zip': '6041', 'city': 'Gosselies', 'state': 'BEL', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.46936, 'lon': 4.43324}}, {'zip': '6534', 'city': 'Gozée', 'state': 'BEL', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.33461, 'lon': 4.35273}}, {'zip': '3271', 'city': 'Zichem', 'state': 'BEL', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.00187, 'lon': 4.98316}}, {'zip': '2060', 'city': 'Antwerp', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.22047, 'lon': 4.40026}}, {'zip': '2490', 'city': 'Balen', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.16837, 'lon': 5.17027}}, {'zip': '1420', 'city': "Braine-l'Alleud", 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.68363, 'lon': 4.36784}}, {'zip': '1000', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '1070', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '1200', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '5100', 'city': 'Erpent', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.45116, 'lon': 4.90557}}, {'zip': '5310', 'city': 'Éghezée', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.59076, 'lon': 4.91175}}, {'zip': '9500', 'city': 'Geraardsbergen', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.77343, 'lon': 3.88223}}, {'zip': '6060', 'city': 'Gilly', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.42449, 'lon': 4.4789}}, {'zip': '3545', 'city': 'Halen', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.94837, 'lon': 5.11096}}, {'zip': '3500', 'city': 'Hasselt', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.93106, 'lon': 5.33781}}, {'zip': '4802', 'city': 'Heusy', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.57457, 'lon': 5.86618}}, {'zip': '8900', 'city': 'Ieper', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85114, 'lon': 2.88569}}, {'zip': '8300', 'city': 'Knokke-Heist', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.35, 'lon': 3.26667}}, {'zip': '9280', 'city': 'Lebbeke', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.00464, 'lon': 4.13457}}, {'zip': '4000', 'city': 'Liège', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': '3680', 'city': 'Maaseik', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.09802, 'lon': 5.78379}}, {'zip': '4960', 'city': 'Malmedy', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.42686, 'lon': 6.02794}}, {'zip': '2800', 'city': 'Mechelen', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.02574, 'lon': 4.47762}}, {'zip': '1820', 'city': 'Melsbroek', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.91559, 'lon': 4.47985}}, {'zip': '2170', 'city': 'Merksem', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.24623, 'lon': 4.44903}}, {'zip': '4420', 'city': 'Montegnée', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.64576, 'lon': 5.51411}}, {'zip': '5360', 'city': 'Natoye', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.34294, 'lon': 5.058}}, {'zip': '3583', 'city': 'Paal-Beringen', 'country': 'Belgium', 'facility': 'Novartis Investigative Site'}, {'zip': '9600', 'city': 'Ronse', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.74574, 'lon': 3.6005}}, {'zip': '6887', 'city': 'Saint-Médard', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.81538, 'lon': 5.32795}}, {'zip': '4100', 'city': 'Seraing', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.58362, 'lon': 5.50115}}, {'zip': '7500', 'city': 'Tournai', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.60715, 'lon': 3.38932}}, {'zip': '4800', 'city': 'Verviers', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.58907, 'lon': 5.86241}}, {'zip': '1800', 'city': 'Vilvoorde', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.92814, 'lon': 4.42938}}, {'zip': '9620', 'city': 'Zottegem', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.86955, 'lon': 3.81052}}, {'zip': '680 01', 'city': 'Boskovice', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.48751, 'lon': 16.65997}}, {'zip': '25001', 'city': 'Brandýs nad Labem', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.18356, 'lon': 14.67244}}, {'zip': '61200', 'city': 'Brno-Kralovo Pole', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site'}, {'zip': '471 54', 'city': 'Cvikov', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.77668, 'lon': 14.63298}}, {'zip': '580 01', 'city': 'Havlíčkův Brod', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.6069, 'lon': 15.57937}}, {'zip': '43111', 'city': 'Jirkov', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.49979, 'lon': 13.44769}}, {'zip': '66434', 'city': 'Kuřim', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.29852, 'lon': 16.53144}}, {'zip': '460 01', 'city': 'Liberec', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.76711, 'lon': 15.05619}}, {'zip': '410 02', 'city': 'Lovosice', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.51504, 'lon': 14.05103}}, {'zip': '27711', 'city': 'Neratovice', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.25926, 'lon': 14.51759}}, {'zip': '708 68', 'city': 'Ostrava', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'zip': '530 09', 'city': 'Pardubice', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'zip': '33011', 'city': 'Pilsen', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.74747, 'lon': 13.37759}}, {'zip': '331 01', 'city': 'Pilsen', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.74747, 'lon': 13.37759}}, {'zip': '108 00', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '130 00', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '140 46', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '142 00', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '14800', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '163 00', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '19000', 'city': 'Prague', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '337 22', 'city': 'Rokycany', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.7427, 'lon': 13.59459}}, {'zip': '25219', 'city': 'Rudná', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.03502, 'lon': 14.23435}}, {'zip': '415 01', 'city': 'Teplice', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.6404, 'lon': 13.82451}}, {'zip': '674 01', 'city': 'Třebíč', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.21492, 'lon': 15.88166}}, {'zip': '40747', 'city': 'Varnsdorf', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.91154, 'lon': 14.61824}}, {'zip': '672 01', 'city': 'Znojmo', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.8555, 'lon': 16.0488}}, {'zip': '438 01', 'city': 'Žatec', 'state': 'Czech Republic', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.32717, 'lon': 13.54577}}, {'zip': '182 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '3450', 'city': 'Alleroed', 'country': 'Denmark', 'facility': 'Novartis Investigative Site'}, {'zip': '2670', 'city': 'Greve', 'country': 'Denmark', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.58333, 'lon': 12.3}}, {'zip': '4690', 'city': 'Haslev', 'country': 'Denmark', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.32346, 'lon': 11.96389}}, {'zip': '2860', 'city': 'Søborg', 'country': 'Denmark', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.08481, 'lon': 12.31803}}, {'zip': '3500', 'city': 'Værløse', 'country': 'Denmark', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.78251, 'lon': 12.36856}}, {'zip': '72714', 'city': 'Paide', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.88768, 'lon': 25.54042}}, {'zip': '10138', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '10617', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '13419', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '13619', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '51014', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '37044', 'city': 'Tours', 'state': 'Indre Et Loire', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '91640', 'city': 'Briis-sous-Forges', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.62399, 'lon': 2.12112}}, {'zip': '63400', 'city': 'Chamalières', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.77364, 'lon': 3.06703}}, {'zip': '86100', 'city': 'Châtellerault', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.81705, 'lon': 0.54518}}, {'zip': '57600', 'city': 'Forbach', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.18848, 'lon': 6.89255}}, {'zip': '61305', 'city': "L'Aigle", 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.76216, 'lon': 0.62746}}, {'zip': '35340', 'city': 'La Bouëxière', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.18404, 'lon': -1.43843}}, {'zip': '13003', 'city': 'Marseille', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '34080', 'city': 'Montpellier', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '49610', 'city': 'Mûrs-Erigné', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.39592, 'lon': -0.55293}}, {'zip': '06000', 'city': 'Nice', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '64500', 'city': 'Saint-Jean-de-Luz', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.38871, 'lon': -1.66267}}, {'zip': '06721', 'city': 'Saint-Laurent-du-Var', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.67323, 'lon': 7.19}}, {'zip': '97448', 'city': 'Saint-Pierre', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.29282, 'lon': 5.40682}}, {'zip': '67000', 'city': 'Strasbourg', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '83000', 'city': 'Toulon', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.12442, 'lon': 5.92836}}, {'zip': '30159', 'city': 'Hanover', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '31224', 'city': 'Peine', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.31928, 'lon': 10.2352}}, {'zip': '56068', 'city': 'Koblenz', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Novartis Investigative Site'}, {'zip': '48231', 'city': 'Warendorf', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.95109, 'lon': 7.98756}}, {'zip': '45127', 'city': 'Essen', 'state': 'Rhineland-Palatinate', 'country': 'Germany', 'facility': 'Novartis Investigative Site'}, {'zip': '03050', 'city': 'Cottbus', 'state': 'Saxony', 'country': 'Germany', 'facility': 'Novartis Investigative Site'}, {'zip': '12502', 'city': 'Geesthacht', 'state': 'Schleswig-Holstein', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.4366, 'lon': 10.37339}}, {'zip': '09456', 'city': 'Annaberg-Buchholz', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.57953, 'lon': 13.00627}}, {'zip': '08209', 'city': 'Auerbach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.51155, 'lon': 12.40083}}, {'zip': '86150', 'city': 'Augsburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.37154, 'lon': 10.89851}}, {'zip': '97616', 'city': 'Bad Neustadt an der Saale', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.32174, 'lon': 10.20673}}, {'zip': '32105', 'city': 'Bad Salzuflen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.0862, 'lon': 8.74434}}, {'zip': '86825', 'city': 'Bad Wörishofen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.00674, 'lon': 10.59666}}, {'zip': '96049', 'city': 'Bamberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.89873, 'lon': 10.90067}}, {'zip': '64625', 'city': 'Bensheim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.68369, 'lon': 8.61839}}, {'zip': '10117', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10119', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10367', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10625', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10629', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10717', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10787', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12099', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12157', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12159', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12165', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12203', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12627', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '12687', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13057', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13086', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13156', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13187', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '13507', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '14059', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': 'D-12165', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '33617', 'city': 'Bielefeld', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.03333, 'lon': 8.53333}}, {'zip': '44787', 'city': 'Bochum', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'zip': '53119', 'city': 'Bonn', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'zip': '53123', 'city': 'Bonn', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'zip': '46240', 'city': 'Bottrop', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.52392, 'lon': 6.9285}}, {'zip': '76646', 'city': 'Bruchsal', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.12426, 'lon': 8.59804}}, {'zip': '30938', 'city': 'Burgwedel', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.65148, 'lon': 9.90769}}, {'zip': '50668', 'city': 'Cologne', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '50937', 'city': 'Cologne', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '51069', 'city': 'Cologne', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '51605', 'city': 'Cologne', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'zip': '57567', 'city': 'Daaden', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.73333, 'lon': 7.96667}}, {'zip': '85221', 'city': 'Dachau', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.26, 'lon': 11.43402}}, {'zip': '94469', 'city': 'Deggendorf', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.84085, 'lon': 12.96068}}, {'zip': '73328', 'city': 'Deggingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.5971, 'lon': 9.71891}}, {'zip': '04509', 'city': 'Delitzsch', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.52546, 'lon': 12.34284}}, {'zip': '44263', 'city': 'Dortmund', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.51494, 'lon': 7.466}}, {'zip': '01069', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '01129', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '52349', 'city': 'Düren', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.80434, 'lon': 6.49299}}, {'zip': '40211', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '40489', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '99817', 'city': 'Eisenach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.9807, 'lon': 10.31522}}, {'zip': '04910', 'city': 'Elsterwerda', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.46043, 'lon': 13.52001}}, {'zip': '91054', 'city': 'Erlangen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.59099, 'lon': 11.00783}}, {'zip': '45138', 'city': 'Essen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '45147', 'city': 'Essen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '45276', 'city': 'Essen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '45277', 'city': 'Essen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '45355', 'city': 'Essen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '45359', 'city': 'Essen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '54343', 'city': 'Föhren', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.85929, 'lon': 6.7648}}, {'zip': '35066', 'city': 'Frankenberg (Eder)', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.0589, 'lon': 8.80077}}, {'zip': '60389', 'city': 'Frankfurt', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.68333, 'lon': 10.53333}}, {'zip': '60313', 'city': 'Frankfurt am Main', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}, {'zip': '79104', 'city': 'Freiburg im Breisgau', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'zip': '57258', 'city': 'Freudenberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.89741, 'lon': 7.87415}}, {'zip': '15517', 'city': 'Fürstenwalde', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.36067, 'lon': 14.06185}}, {'zip': '82467', 'city': 'Garmisch-Partenkirchen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.49209, 'lon': 11.09576}}, {'zip': '82131', 'city': 'Gauting', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.06919, 'lon': 11.37703}}, {'zip': '35390', 'city': 'Giessen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.58727, 'lon': 8.67554}}, {'zip': '38518', 'city': 'Gifhorn', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.47774, 'lon': 10.5511}}, {'zip': '47574', 'city': 'Goch', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.67873, 'lon': 6.15895}}, {'zip': '02826', 'city': 'Görlitz', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.15518, 'lon': 14.98853}}, {'zip': '51343', 'city': 'Gummersbach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.02608, 'lon': 7.56473}}, {'zip': '33330', 'city': 'Gütersloh', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.90693, 'lon': 8.37853}}, {'zip': '58089', 'city': 'Hagen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.36081, 'lon': 7.47168}}, {'zip': '38820', 'city': 'Halberstadt', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.89562, 'lon': 11.05622}}, {'zip': '06108', 'city': 'Halle', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.48158, 'lon': 11.97947}}, {'zip': '20253', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '20354', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '20357', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22143', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22299', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22335', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22527', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '30163', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '30173', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '30419', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '69117', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '06333', 'city': 'Hettstedt', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.6503, 'lon': 11.51146}}, {'zip': '31134', 'city': 'Hildesheim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.15077, 'lon': 9.95112}}, {'zip': '02977', 'city': 'Hoyerswerda', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.43787, 'lon': 14.23549}}, {'zip': '07740', 'city': 'Jena', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.92878, 'lon': 11.5899}}, {'zip': '39319', 'city': 'Jerichow', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.50049, 'lon': 12.02383}}, {'zip': '59174', 'city': 'Kamen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.59231, 'lon': 7.6638}}, {'zip': '76199', 'city': 'Karlsruhe', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.00937, 'lon': 8.40444}}, {'zip': '34117', 'city': 'Kassel', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.31667, 'lon': 9.5}}, {'zip': '34121', 'city': 'Kassel', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.31667, 'lon': 9.5}}, {'zip': '24105', 'city': 'Kiel', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '47533', 'city': 'Kleve', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.78826, 'lon': 6.13865}}, {'zip': '06366', 'city': 'Köthen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.75185, 'lon': 11.97093}}, {'zip': '76829', 'city': 'Landau-Pfalz', 'country': 'Germany', 'facility': 'Novartis Investigative Site'}, {'zip': '86899', 'city': 'Landsberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.52698, 'lon': 12.16076}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '04109', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '04207', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '04275', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '04357', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '71229', 'city': 'Leonberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.8, 'lon': 9.01667}}, {'zip': '51379', 'city': 'Leverkusen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.0303, 'lon': 6.98432}}, {'zip': '67117', 'city': 'Limburgerhof', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.42444, 'lon': 8.39194}}, {'zip': '32584', 'city': 'Löhne', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.18848, 'lon': 8.6922}}, {'zip': '71640', 'city': 'Ludwigsburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.89731, 'lon': 9.19161}}, {'zip': '67061', 'city': 'Ludwigshafen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.81663, 'lon': 9.06138}}, {'zip': '67067', 'city': 'Ludwigshafen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.81663, 'lon': 9.06138}}, {'zip': '23554', 'city': 'Lübeck', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'zip': '58507', 'city': 'Lüdenscheid', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.21977, 'lon': 7.6273}}, {'zip': '39112', 'city': 'Magdeburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.13129, 'lon': 11.63189}}, {'zip': '35033', 'city': 'Marburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'zip': '35037', 'city': 'Marburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'zip': 'D-35037', 'city': 'Marburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'zip': '56727', 'city': 'Mayen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.32797, 'lon': 7.22277}}, {'zip': '38527', 'city': 'Meine', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.38493, 'lon': 10.53932}}, {'zip': '01662', 'city': 'Meissen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.16158, 'lon': 13.4737}}, {'zip': '58706', 'city': 'Menden', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.44337, 'lon': 7.77825}}, {'zip': '32423', 'city': 'Minden', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.28953, 'lon': 8.91455}}, {'zip': '09648', 'city': 'Mittweida', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.98622, 'lon': 12.97537}}, {'zip': '45468', 'city': 'Mülheim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.43218, 'lon': 6.87967}}, {'zip': '80335', 'city': 'München', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '80802', 'city': 'München', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '97702', 'city': 'Münnerstadt', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.24636, 'lon': 10.20187}}, {'zip': '63263', 'city': 'Neu-Isenburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.04832, 'lon': 8.69406}}, {'zip': '89231', 'city': 'Neu-Ulm', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.39279, 'lon': 10.01112}}, {'zip': '66539', 'city': 'Neunkirchen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.34449, 'lon': 7.18045}}, {'zip': '41462', 'city': 'Neuss', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.19807, 'lon': 6.68504}}, {'zip': '56564', 'city': 'Neuwied', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.4336, 'lon': 7.47057}}, {'zip': '37154', 'city': 'Northeim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.70662, 'lon': 9.99997}}, {'zip': '90443', 'city': 'Nuremberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.45421, 'lon': 11.07752}}, {'zip': '90478', 'city': 'Nuremberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.45421, 'lon': 11.07752}}, {'zip': '90587', 'city': 'Obermichelbach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.53117, 'lon': 10.90891}}, {'zip': '04758', 'city': 'Oschatz', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.30001, 'lon': 13.10984}}, {'zip': '39387', 'city': 'Oschersleben', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.03039, 'lon': 11.22898}}, {'zip': '49074', 'city': 'Osnabrück', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.27264, 'lon': 8.0498}}, {'zip': '26871', 'city': 'Papenburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.07769, 'lon': 7.41516}}, {'zip': '94032', 'city': 'Passau', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.5665, 'lon': 13.43122}}, {'zip': '08523', 'city': 'Plauen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.4973, 'lon': 12.13782}}, {'zip': '14467', 'city': 'Potsdam', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.39886, 'lon': 13.06566}}, {'zip': '14469', 'city': 'Potsdam', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.39886, 'lon': 13.06566}}, {'zip': '83209', 'city': 'Prien A. Chiemsee', 'country': 'Germany', 'facility': 'Novartis Investigative Site'}, {'zip': '01445', 'city': 'Radebeul', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.10654, 'lon': 13.66047}}, {'zip': '40878', 'city': 'Ratingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.29724, 'lon': 6.84929}}, {'zip': '56316', 'city': 'Raubach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.57489, 'lon': 7.62496}}, {'zip': '23858', 'city': 'Reinfeld', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.8311, 'lon': 10.49227}}, {'zip': '48431', 'city': 'Rheine', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.28509, 'lon': 7.44055}}, {'zip': '67688', 'city': 'Rodenbach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.15, 'lon': 9.03333}}, {'zip': '91154', 'city': 'Roth', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.24762, 'lon': 11.09111}}, {'zip': '15562', 'city': 'Rudersdorf', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.1, 'lon': 11.45}}, {'zip': '65428', 'city': 'Rüsselsheim am Main', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.98955, 'lon': 8.42251}}, {'zip': '07318', 'city': 'Saalfeld', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.64826, 'lon': 11.36536}}, {'zip': '66111', 'city': 'Saarbrücken', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.23262, 'lon': 7.00982}}, {'zip': '24837', 'city': 'Schleswig', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.52021, 'lon': 9.56829}}, {'zip': '91126', 'city': 'Schwabach', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.33047, 'lon': 11.02346}}, {'zip': '16303', 'city': 'Schwedt', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.05963, 'lon': 14.28154}}, {'zip': '19055', 'city': 'Schwerin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.62937, 'lon': 11.41316}}, {'zip': '68723', 'city': 'Schwetzingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.38217, 'lon': 8.5823}}, {'zip': '57076', 'city': 'Siegen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.87481, 'lon': 8.02431}}, {'zip': '74889', 'city': 'Sinsheim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.2529, 'lon': 8.87867}}, {'zip': '42651', 'city': 'Solingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.17343, 'lon': 7.0845}}, {'zip': '42665', 'city': 'Solingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.17343, 'lon': 7.0845}}, {'zip': '42697', 'city': 'Solingen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.17343, 'lon': 7.0845}}, {'zip': '96515', 'city': 'Sonneberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.3592, 'lon': 11.17463}}, {'zip': '15344', 'city': 'Strausberg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.57859, 'lon': 13.88741}}, {'zip': '06682', 'city': 'Teuchern', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.12094, 'lon': 12.0241}}, {'zip': '89073', 'city': 'Ulm', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '26203', 'city': 'Wardenburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.05938, 'lon': 8.19669}}, {'zip': '82362', 'city': 'Weilheim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.84147, 'lon': 11.15484}}, {'zip': '73642', 'city': 'Welzheim', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.87675, 'lon': 9.63434}}, {'zip': '49492', 'city': 'Westerkappeln', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.31667, 'lon': 7.88333}}, {'zip': '69168', 'city': 'Wiesloch', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.29504, 'lon': 8.69846}}, {'zip': '57537', 'city': 'Wissen', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.77915, 'lon': 7.73466}}, {'zip': '58452', 'city': 'Witten', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.44362, 'lon': 7.35258}}, {'zip': '38448', 'city': 'Wolfsburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.42452, 'lon': 10.7815}}, {'zip': '55597', 'city': 'Wöllstein', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.90441, 'lon': 9.96488}}, {'zip': '39261', 'city': 'Zerbst', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.9662, 'lon': 12.08517}}, {'zip': '115 27', 'city': 'Athens', 'state': 'GR', 'country': 'Greece', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '564 29', 'city': 'Thessaloniki', 'state': 'GR', 'country': 'Greece', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': 'GR 62 100', 'city': 'Serres', 'country': 'Greece', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.08499, 'lon': 23.54757}}, {'zip': '9024', 'city': 'Győr', 'state': 'HUN', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'zip': '2440', 'city': 'Százhalombatta', 'state': 'HUN', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.32949, 'lon': 18.93878}}, {'zip': '2700', 'city': 'Cegléd', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.17266, 'lon': 19.79952}}, {'zip': '4026', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '3000', 'city': 'Hatvan', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.66667, 'lon': 19.68333}}, {'zip': '2900', 'city': 'Komárom', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.74318, 'lon': 18.11913}}, {'zip': '6900', 'city': 'Makó', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.21667, 'lon': 20.48333}}, {'zip': '4700', 'city': 'Mátészalka', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.95528, 'lon': 22.32348}}, {'zip': '7624', 'city': 'Pécs', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '7635', 'city': 'Pécs', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '6722', 'city': 'Szeged', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'zip': '2800', 'city': 'Tatabánya', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.59247, 'lon': 18.38099}}, {'zip': '2045', 'city': 'Törökbálint', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.42931, 'lon': 18.91356}}, {'zip': 'V94 F858', 'city': 'County Limerick', 'country': 'Ireland', 'facility': 'Novartis Investigative Site'}, {'zip': '24', 'city': 'Dublin', 'country': 'Ireland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': 'DUBLIN 8', 'city': 'Dublin', 'country': 'Ireland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': '60128', 'city': 'Ancona', 'state': 'AN', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.60717, 'lon': 13.5103}}, {'zip': '83100', 'city': 'Avellino', 'state': 'AV', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.91494, 'lon': 14.79103}}, {'zip': '70123', 'city': 'Bari', 'state': 'BA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'zip': '70124', 'city': 'Bari', 'state': 'BA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'zip': '70038', 'city': 'Terlizzi', 'state': 'BA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.12905, 'lon': 16.54536}}, {'zip': '70019', 'city': 'Triggiano', 'state': 'BA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.06549, 'lon': 16.92501}}, {'zip': '24058', 'city': 'Romano di Lombardia', 'state': 'BG', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.52081, 'lon': 9.7544}}, {'zip': '32032', 'city': 'Feltre', 'state': 'BL', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.02085, 'lon': 11.90031}}, {'zip': '82037', 'city': 'Telese Terme', 'state': 'BN', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.21752, 'lon': 14.52681}}, {'zip': '72027', 'city': 'San Pietro Vernotico', 'state': 'BR', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4889, 'lon': 17.99752}}, {'zip': '25123', 'city': 'Brescia', 'state': 'BS', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'zip': '86100', 'city': 'Campobasso', 'state': 'CB', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.55947, 'lon': 14.66737}}, {'zip': '81025', 'city': 'Marcianise', 'state': 'CE', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.03064, 'lon': 14.29868}}, {'zip': '93100', 'city': 'Caltanissetta', 'state': 'CL', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.49025, 'lon': 14.06216}}, {'zip': '12037', 'city': 'Saluzzo', 'state': 'CN', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.64671, 'lon': 7.49309}}, {'zip': '95100', 'city': 'Catania', 'state': 'CT', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'zip': '95122', 'city': 'Catania', 'state': 'CT', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'zip': '95126', 'city': 'Catania', 'state': 'CT', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'zip': '47100', 'city': 'Forlì', 'state': 'FC', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.22177, 'lon': 12.04144}}, {'zip': '71100', 'city': 'Foggia', 'state': 'FG', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.45845, 'lon': 15.55188}}, {'zip': '71016', 'city': 'San Severo', 'state': 'FG', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.68564, 'lon': 15.38148}}, {'zip': '50122', 'city': 'Florence', 'state': 'FI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'zip': '50134', 'city': 'Florence', 'state': 'FI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'zip': '16100', 'city': 'Genova', 'state': 'GE', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'zip': '57124', 'city': 'Livorno', 'state': 'LI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.54427, 'lon': 10.32615}}, {'zip': '26900', 'city': 'Lodi', 'state': 'LO', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.30989, 'lon': 9.50085}}, {'zip': '55041', 'city': 'Lido di Camaiore', 'state': 'LU', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.90012, 'lon': 10.2269}}, {'zip': '20900', 'city': 'Monza', 'state': 'MB', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'MI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '08100', 'city': 'Nuoro', 'state': 'NU', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.31991, 'lon': 9.32568}}, {'zip': '90127', 'city': 'Palermo', 'state': 'PA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'zip': '90146', 'city': 'Palermo', 'state': 'PA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'zip': '29100', 'city': 'Piacenza', 'state': 'PC', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.05242, 'lon': 9.69342}}, {'zip': '35013', 'city': 'Cittadella', 'state': 'PD', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.64523, 'lon': 11.78453}}, {'zip': '56124', 'city': 'Pisa', 'state': 'PI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'zip': '33170', 'city': 'Pordenone', 'state': 'PN', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.95689, 'lon': 12.66051}}, {'zip': '27058', 'city': 'Voghera', 'state': 'PV', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99151, 'lon': 9.01175}}, {'zip': '00128', 'city': 'Roma', 'state': 'RM', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '00161', 'city': 'Roma', 'state': 'RM', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '00163', 'city': 'Roma', 'state': 'RM', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '00189', 'city': 'Roma', 'state': 'RM', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '47838', 'city': 'Riccione', 'state': 'RN', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.99942, 'lon': 12.65689}}, {'zip': '53100', 'city': 'Siena', 'state': 'SI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 43.31822, 'lon': 11.33064}}, {'zip': '23035', 'city': 'Sondalo', 'state': 'SO', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.32983, 'lon': 10.3269}}, {'zip': '07100', 'city': 'Sassari', 'state': 'SS', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.72586, 'lon': 8.55552}}, {'zip': '10043', 'city': 'Orbassano', 'state': 'TO', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.00547, 'lon': 7.53813}}, {'zip': '05100', 'city': 'Terni', 'state': 'TR', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}}, {'zip': '31044', 'city': 'Montebelluna', 'state': 'TV', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.77504, 'lon': 12.04904}}, {'zip': '31029', 'city': 'Vittorio Veneto', 'state': 'TV', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.98026, 'lon': 12.30065}}, {'zip': '21052', 'city': 'Busto Arsizio', 'state': 'VA', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.61128, 'lon': 8.84914}}, {'zip': '36071', 'city': 'Arzignano', 'state': 'VI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.52027, 'lon': 11.33446}}, {'zip': '36100', 'city': 'Vicenza', 'state': 'VI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.54672, 'lon': 11.5475}}, {'zip': '37012', 'city': 'Bussolengo', 'state': 'VR', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.46903, 'lon': 10.85371}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '10149', 'city': 'Torino', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'zip': '4501', 'city': 'Balvi', 'state': 'LVA', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 57.1313, 'lon': 27.26583}}, {'zip': 'LV-2015', 'city': 'Jūrmala', 'state': 'LVA', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.968, 'lon': 23.77038}}, {'zip': '1011', 'city': 'Riga', 'state': 'LV', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-1038', 'city': 'Riga', 'state': 'LV', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-5401', 'city': 'Daugavpils', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.88333, 'lon': 26.53333}}, {'zip': 'LV 1002', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-1001', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LT-10207', 'city': 'Vilnius', 'state': 'LTU', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': 'LT-50128', 'city': 'Kaunas', 'state': 'LT', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': '01117', 'city': 'Vilnius', 'state': 'LT', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': 'LT-62114', 'city': 'Alytus', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.39574, 'lon': 24.03885}}, {'zip': '3007', 'city': 'Kaunas', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': 'LT-92288', 'city': 'Klaipėda', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.7068, 'lon': 21.13912}}, {'zip': 'LT-28151', 'city': 'Utena', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.4978, 'lon': 25.60462}}, {'zip': '06122', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': 'LT-08661', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '6800', 'city': 'Førde', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 61.45217, 'lon': 5.85717}}, {'zip': '2040', 'city': 'Kløfta', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 60.07407, 'lon': 11.13805}}, {'zip': '3420', 'city': 'Lierskogen', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.81978, 'lon': 10.33084}}, {'zip': '0190', 'city': 'Oslo', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}, {'zip': '0953', 'city': 'Oslo', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}, {'zip': '2020', 'city': 'Skedsmokorset', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 60.00459, 'lon': 11.03278}}, {'zip': '3734', 'city': 'Skien', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.20962, 'lon': 9.60897}}, {'zip': '4005', 'city': 'Stavanger', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.97005, 'lon': 5.73332}}, {'zip': '4056', 'city': 'Tananger', 'country': 'Norway', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.93618, 'lon': 5.5741}}, {'zip': '15-044', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '31-024', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '05-100', 'city': 'Nowy Dwór Mazowiecki', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.43022, 'lon': 20.71652}}, {'zip': '63-400', 'city': 'Ostrów Wielkopolski', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.65501, 'lon': 17.80686}}, {'zip': '64-920', 'city': 'Piła', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.15145, 'lon': 16.73782}}, {'zip': '81-741', 'city': 'Sopot', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'zip': '01-138', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '51-162', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '3814-501', 'city': 'Aveiro', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.64575, 'lon': -8.64643}}, {'zip': '4754-909', 'city': 'Barcelos', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.53174, 'lon': -8.61843}}, {'zip': '3041-853', 'city': 'Coimbra', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.20686, 'lon': -8.41996}}, {'zip': '4835-044', 'city': 'Guimarães', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.44443, 'lon': -8.29619}}, {'zip': '1169-024', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1349-019', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '4200 319', 'city': 'Porto', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'zip': '2600-009', 'city': 'Vila Franca de Xira', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.95525, 'lon': -8.98966}}, {'zip': '440-230', 'city': 'Vila Nova de Gaia', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.12401, 'lon': -8.61241}}, {'zip': '030303', 'city': 'Bucharest', 'state': 'District 3', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '700115', 'city': 'Iași', 'state': 'Jud. Iasi', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '600252', 'city': 'Bacau', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.56718, 'lon': 26.91384}}, {'zip': '077025', 'city': 'Bragadiru', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.37111, 'lon': 25.9775}}, {'zip': '900591', 'city': 'Constanța', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.18073, 'lon': 28.63432}}, {'zip': '240564', 'city': 'Râmnicu Vâlcea', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.1, 'lon': 24.36667}}, {'zip': '720284', 'city': 'Suceava', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.63333, 'lon': 26.25}}, {'zip': '300736', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '454021', 'city': 'Chelyabinsk', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.1611, 'lon': 61.42877}}, {'zip': '420012', 'city': "Kazan'", 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'zip': '650029', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '101990', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '125315', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '603126', 'city': 'N.Novgorod', 'country': 'Russia', 'facility': 'Novartis Investigative Site'}, {'zip': '630099', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '390026', 'city': 'Ryazan', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.62696, 'lon': 39.70415}}, {'zip': '194354', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197022', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '410012', 'city': 'Saratov', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.54048, 'lon': 45.9901}}, {'zip': '214019', 'city': 'Smolensk', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.77826, 'lon': 32.05088}}, {'zip': '634050', 'city': 'Tomsk', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.50049, 'lon': 84.98216}}, {'zip': '450000', 'city': 'Ufa', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'zip': '150003', 'city': 'Yaroslavl', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 57.62987, 'lon': 39.87368}}, {'zip': '085 01', 'city': 'Bardejov', 'state': 'Slovak Republic', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.29175, 'lon': 21.27271}}, {'zip': '972 01', 'city': 'Bojnice', 'state': 'Slovak Republic', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.78511, 'lon': 18.5864}}, {'zip': '033 01', 'city': 'Liptovský Hrádok', 'state': 'Slovak Republic', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.03962, 'lon': 19.72335}}, {'zip': '02901', 'city': 'Námestovo', 'state': 'Slovensko', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.4079, 'lon': 19.48032}}, {'zip': '077 01', 'city': 'Kráľovský Chlmec', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.42336, 'lon': 21.97944}}, {'zip': '034 01', 'city': 'Levice', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.21563, 'lon': 18.60705}}, {'zip': '058 01', 'city': 'Poprad', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.06144, 'lon': 20.29798}}, {'zip': '080 01', 'city': 'Prešov', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.99923, 'lon': 21.2355}}, {'zip': '08001', 'city': 'Prešov', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.99923, 'lon': 21.2355}}, {'zip': '927 01', 'city': 'Šaľa', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.15127, 'lon': 17.88062}}, {'zip': '943 11', 'city': 'Štúrovo', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.79495, 'lon': 18.7175}}, {'zip': '917 75', 'city': 'Trnava', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.37773, 'lon': 17.58603}}, {'zip': '95201', 'city': 'Vráble', 'country': 'Slovakia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.24371, 'lon': 18.30846}}, {'zip': '4204', 'city': 'Golnik', 'country': 'Slovenia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.33333, 'lon': 14.33333}}, {'zip': '4000', 'city': 'Kranj', 'country': 'Slovenia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.23887, 'lon': 14.35561}}, {'zip': '2000', 'city': 'Maribor', 'country': 'Slovenia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.55583, 'lon': 15.64593}}, {'zip': '9000', 'city': 'Murska Sobota', 'country': 'Slovenia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.66264, 'lon': 16.16643}}, {'zip': '14004', 'city': 'Córdoba', 'state': 'Andalusia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'zip': '29600', 'city': 'Marbella', 'state': 'Andalusia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 36.51543, 'lon': -4.88583}}, {'zip': '29603', 'city': 'Marbella', 'state': 'Andalusia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 36.51543, 'lon': -4.88583}}, {'zip': '29010', 'city': 'Málaga', 'state': 'Andalusia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '07198', 'city': 'Mallorca', 'state': 'Balearic Islands', 'country': 'Spain', 'facility': 'Novartis Investigative Site'}, {'zip': '07014', 'city': 'Palma de Mallorca', 'state': 'Balearic Islands', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.56939, 'lon': 2.65024}}, {'zip': '08917', 'city': 'Badalona', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}, {'zip': '08540', 'city': 'Centelles', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.79746, 'lon': 2.21902}}, {'zip': '08303', 'city': 'Mataró', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.54211, 'lon': 2.4445}}, {'zip': '08208', 'city': 'Sabadell', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'zip': '08970', 'city': 'Sant Joan Despí', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.36718, 'lon': 2.0574}}, {'zip': '08500', 'city': 'Vic', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.93012, 'lon': 2.25486}}, {'zip': '24400', 'city': 'Ponferrada', 'state': 'Castille and León', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.54664, 'lon': -6.59619}}, {'zip': '37007', 'city': 'Salamanca', 'state': 'Castille and León', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.96882, 'lon': -5.66388}}, {'zip': '08916', 'city': 'Badalona', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}, {'zip': '08035', 'city': 'Barcelona', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08360', 'city': 'Canet de Mar', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.59054, 'lon': 2.58116}}, {'zip': '08830', 'city': 'Sant Boi de Llobregat', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.34357, 'lon': 2.03659}}, {'zip': '08500', 'city': 'Vic', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.93012, 'lon': 2.25486}}, {'zip': '10003', 'city': 'Cáceres', 'state': 'Extremadura', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47649, 'lon': -6.37224}}, {'zip': '06800', 'city': 'Mérida', 'state': 'Extremadura', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.91802, 'lon': -6.34292}}, {'zip': '18600', 'city': 'Motril', 'state': 'Granada', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 36.75066, 'lon': -3.5179}}, {'zip': '28342', 'city': 'Valdemoro', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.19081, 'lon': -3.67887}}, {'zip': '28022', 'city': 'Madrid', 'state': 'Madrid, Communidad de', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28933', 'city': 'Móstoles', 'state': 'Madrid, Communidad de', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.32234, 'lon': -3.86496}}, {'zip': '46600', 'city': 'Alzira', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.15, 'lon': -0.43333}}, {'zip': '03501', 'city': 'Benidorm', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.53816, 'lon': -0.13098}}, {'zip': '46520', 'city': 'Port de Sagunt', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.6622, 'lon': -0.21749}}, {'zip': '46010', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '46014', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '46015', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '46017', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '46019', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '28034', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '50009', 'city': 'Zaragoza', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}, {'zip': '413 46', 'city': 'Gothenburg', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'zip': '134 44', 'city': 'Gustavsberg', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.32684, 'lon': 18.38975}}, {'zip': '252 25', 'city': 'Helsingborg', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.04673, 'lon': 12.69437}}, {'zip': '236 32', 'city': 'Höllviken', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.40982, 'lon': 12.9558}}, {'zip': '456 31', 'city': 'Kungshamn', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.36305, 'lon': 11.25938}}, {'zip': '216 43', 'city': 'Limhamn', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.58333, 'lon': 12.95}}, {'zip': '222 22', 'city': 'Lund', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'zip': '252 70', 'city': 'Råå', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.0, 'lon': 12.73333}}, {'zip': '907 40', 'city': 'Umeå', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 63.82842, 'lon': 20.25972}}, {'zip': '421 44', 'city': 'Västra Frölunda', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 57.64667, 'lon': 11.92944}}, {'zip': '587 58', 'city': 'Linköping', 'state': 'Östergötland County', 'country': 'Sweden', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 58.41086, 'lon': 15.62157}}, {'zip': 'HP22 5LB', 'city': 'Aylesbury', 'state': 'Bucks', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.81665, 'lon': -0.81458}}, {'zip': 'PL23 1DT', 'city': 'Fowey', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.33634, 'lon': -4.6386}}, {'zip': 'PL14 3XA', 'city': 'Liskeard', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.4545, 'lon': -4.46517}}, {'zip': 'TR18 AJH', 'city': 'Penzance', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.11861, 'lon': -5.53715}}, {'city': 'Redruth', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.23315, 'lon': -5.22434}}, {'zip': 'PL26 7RL', 'city': 'St Austell', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.3425, 'lon': -4.77442}}, {'zip': 'PL11 2TB', 'city': 'Torpoint', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.37505, 'lon': -4.19566}}, {'zip': 'BA2 3HT', 'city': 'Bath', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.3751, 'lon': -2.36172}}, {'zip': 'PO9 1DQ', 'city': 'Havant', 'state': 'Hampshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.8567, 'lon': -0.98559}}, {'zip': 'LE10 2SE', 'city': 'Burbage', 'state': 'Leicester', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.35184, 'lon': -1.67087}}, {'zip': 'NN11 4DY', 'city': 'Daventry', 'state': 'Northamptonshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.25688, 'lon': -1.16066}}, {'zip': 'NG3 7DQ', 'city': 'Sneinton', 'state': 'Nottingham', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.95159, 'lon': -1.1315}}, {'zip': 'BS26 2BJ', 'city': 'Axbridge', 'state': 'Somerset', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.28466, 'lon': -2.82078}}, {'zip': 'BA11 2FH', 'city': 'Frome', 'state': 'Somerset', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.22834, 'lon': -2.32211}}, {'zip': 'TA1 5DA', 'city': 'Taunton', 'state': 'Somerset', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.01494, 'lon': -3.10293}}, {'zip': 'NE34 0PL', 'city': 'South Shields', 'state': 'Tyne and Wear', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.99859, 'lon': -1.4323}}, {'zip': 'CF63 1BA', 'city': 'Barry', 'state': 'Vale Of Glamorgan', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.39979, 'lon': -3.2838}}, {'zip': 'CV32 4RA', 'city': 'Royal Leamington Spa', 'state': 'Warwickshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.2852, 'lon': -1.52}}, {'zip': 'RH10 7DX', 'city': 'Crawley', 'state': 'West Sussex', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.11303, 'lon': -0.18312}}, {'zip': 'BD9 6RJ', 'city': 'Bradford', 'state': 'West Yorkshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.79391, 'lon': -1.75206}}, {'zip': 'BA14 8QA', 'city': 'Trowbridge', 'state': 'Wiltshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.31889, 'lon': -2.20861}}, {'zip': 'YO32 5UA', 'city': 'Strensall', 'state': 'Yorkshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.03999, 'lon': -1.03512}}, {'zip': 'TN40 1JJ', 'city': 'Bexhill-on-Sea', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85023, 'lon': 0.47095}}, {'zip': 'BS10 6SP', 'city': 'Bristol', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'BS48 1BZ', 'city': 'Bristol', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'CF5 4AD', 'city': 'Cardiff', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'OL9 0LH', 'city': 'Chadderton', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.5448, 'lon': -2.13984}}, {'zip': 'CW1 4QJ', 'city': 'Cheshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site'}, {'zip': 'S40 4AA', 'city': 'Chesterfield', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.25, 'lon': -1.41667}}, {'zip': 'SN14 6GT', 'city': 'Chippenham', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.46, 'lon': -2.12472}}, {'zip': 'CV6 4DD', 'city': 'Coventry', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.40656, 'lon': -1.51217}}, {'zip': 'ML3 8AA', 'city': 'Hamilton', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.76667, 'lon': -4.03333}}, {'zip': 'FY3 7EN', 'city': 'Lancashire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site'}, {'zip': 'M8 9JT', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'ML1 3JX', 'city': 'Motherwell', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.78924, 'lon': -3.99187}}, {'zip': 'OL9 8NH', 'city': 'Oldham', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.54051, 'lon': -2.1183}}, {'zip': 'PL5 3JB', 'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'SY38XQ', 'city': 'Shrewsbury', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.71009, 'lon': -2.75208}}, {'zip': 'DN9 1EP', 'city': 'South Yorkshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site'}, {'zip': 'TS19 8PE', 'city': 'Stockton-on-Tees', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 54.56848, 'lon': -1.3187}}, {'zip': 'CF63 4AR', 'city': 'Vale of Glanmorgan', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site'}, {'zip': 'WD25 7NL', 'city': 'Watford', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.65531, 'lon': -0.39602}}, {'zip': 'SN15 2SB', 'city': 'Wiltshire', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site'}, {'zip': 'ML2 0DP', 'city': 'Wishaw', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.76667, 'lon': -3.91667}}], 'overallOfficials': [{'name': 'Novartis Pharmaceuticals', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novartis Pharmaceuticals'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}